Latest Breaking News On - Hematologic malignancies lymphoma - Page 1 : vimarsana.com

Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment

United statesPierluigi porcuHenry wheelerCharu aggarwalOlivier demariaArthur rouillLorenzo falchiHirva mamdaniAmerican society of clinical oncologyExchange commissionFrench financial markets authorityHoosier cancer research networkCompany annual report on formB cell non hodgkinEuronext parisAmerican society

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeHong kongHaibo qiuMasa lasicaHuafeng wangYifan zhaiAscentage pharmaYuxiang maPrnewswire ascentage pharmaNational reimbursement drug listZhejiang university school of medicineMajor nationalAmerican society of clinical oncologySun yat sen university cancer centerMd anderson cancer center

Data from Across Incyte s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

United kingdomUnited statesTafasitamab monjuviGewinn nurCatalina lovemanPonatinib iclusigSteven steinGreg shertzerEuropean hematology associationLymphoma biology translational researchXencor incMacrogenics incMarrow transplant researchEuropean unionMillennium pharmaceuticals incIncyte corporation

Takeda Pharmaceutical Company Limited: Takeda and Seagen to Highlight ADCETRIS Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

- Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma

United statesJohn cunninghamDavid caouetteRoger danseyPeggy pinkstonRyoko matsumotoChris arendtStephen ansellAmerican society of clinical oncologyTakeda pharmaceutical company limitedEuropean hematology associationImportant safety information european unionSeagen incExchange commissionInternational agency for research on cancerEuropean union

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

United statesJulia neugebauerPeter langmuirMyles cloustonJeanette bressiGilles sallesThomas biegiJohannes duellCatalina lovemanNuwan kurukulasuriyaChristine chiouJenifer antonacciPractice research clinical haematologyUs communicationsJanssen biotech incAmerican society of clinical oncology